Background:
Decentralised elements (DEs) of clinical trials (CTs) such as Telehealth (TH) allow some trial related activities to occur without requiring patients to travel to the clinical trial site.

Methods:
Patients enrolled in oncology CTs at a clinical trial site in Sydney, Australia who underwent at least one TH visit were invited to complete a de-identified modified Study Participant Feedback Questionnaire (SPFQ) to evaluate satisfaction for various aspects of TH, their willingness to continue TH visits and to provide further suggestions as free text. Logistic regression was used to assess factors associated with a willingness to continue TH and suggestions were analysed using content analysis.
Results: 120 patients were invited, and 102 valid questionnaires were returned. Median age was 64 (range 21-92), 65% of pts were male, 77% resided in a metropolitan area and 64% resided within 60 minutes drive to the site. 91% of pts had an advanced stage cancer, 60% were enrolled in a phase I/II trial, and 72% of IPs were administered intravenously. 86% of patients indicated they were satisfied with their experience with TH during their clinical trial and 85% indicated that they would consider additional TH trial visits if this was a future option. There were no significant differences found in future willingness to use TH between patient, cancer or trial-related factors. Patients suggested having an option to choose between in-person or TH, having adequate technology and being able to conduct other trial-related activities remotely would improve their experience.

Conclusion: Patients were overwhelmingly satisfied with their TH visits in an oncology clinical trial and the majority were willing to continue if this was an option for subsequent encounters. Future oncology CT protocols should consider incorporating TH and other DEs as an option if appropriate, to reduce participant travel burden and improve access to CTs.